Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial
Phase 1b data in patients with UC indicate a favorable safety profile for ADS051 with encouraging signals of clinical activity, supporting the advancement to a Phase 2 trial.
Authors
- Parambir S. Dulai (ORCID: https://orcid.org/0000-0002-9514-2321)
- Bharat L. Dixit (ORCID: https://orcid.org/0009-0000-7028-5230)
- Benjamin Miller
- Raisa Tanase
- Barbara Woźniak−Stolarska
- Ronald Farquhar
- Adam S. Cheifetz (ORCID: https://orcid.org/0000-0002-6010-1896)
- Jessica Ravikoff Allegretti (ORCID: https://orcid.org/0000-0003-3585-2425)
- Parviz Ghahramani
- Laurent Chesnel (ORCID: https://orcid.org/0000-0002-4947-5029)
- Tengiz Telia
- Jillian Chapas-Reed (ORCID: https://orcid.org/0000-0001-8870-6347)
- Renu Gupta (ORCID: https://orcid.org/0000-0001-9582-9556)
- Christopher K. Murphy
- Megan Quintas
- A. Stevens
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Ilia State University (GE)
- Moldova State University (MD)
- Io Therapeutics (United States) (US)
- Hexcel (United States) (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2024-12-31
- DOI
- https://doi.org/10.14309/ajg.0000000000003269
- Citations
- 1
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.28